Business Wire Feed

A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer

May 21st, 2026|

Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting provide updates on EVEREST-2 and describe approaches to boost potency and preserve selectivity of TmodTM-based precision cell therapiesCHICAGO--(BUSINESS WIRE)--#ASCO26--A2 Biotherapeutics, Inc. (A2 more...

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

May 21st, 2026|

Primary results from the Phase II ARACOG (AFT-47) head-to-head trial evaluating NUBEQA® (darolutamide) versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer (CRPC) or metastatic hormone-sensitive prostate cancer (mHSPC) will be presented   more...

Surescripts Expands Prior Authorization Automation, Enabling 50% More Prescribers Nationwide to Improve Medication Access for Patients in 2026

May 20th, 2026|

Prescribers Helped Save Patients $19.7 Million with Real-Time Prescription Benefit Since JanuaryARLINGTON, Va.--(BUSINESS WIRE)--#HealthIT--Surescripts®, the nation’s leading health intelligence network, released new data illustrating significant impact of solutions, including Prior Authorization Automation and Real-Time Prescription more...

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.